Elraglusib combined with platinum chemotherapy showed potential benefits in select patients with recurrent, metastatic ...

Welcome to the final edition of The Targeted Pulse of 2025, your weekly wrap-up of the top developments in oncology. This ...

FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager ...

Salvage Efficacy: Most significantly, for the 8 patients who showed no response to initial TCE monotherapy, the addition of ...

The RELATIVITY-098 trial showed no RFS improvement with nivolumab plus relatlimab versus nivolumab alone in resected stage III-IV melanoma. The trial was terminated as it failed to meet its primary ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to include duvelisib (Copiktra) as a category 2A treatment option for cutaneous T-cell ...

In December 2025, the FDA accepted for priority review the supplemental biologics license application for nivolumab-AVD for the treatment of adult and pediatric patients 12 years and older with ...

PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...

This preview introduces the central themes of the upcoming Evolving Paradigms in Oncology program focused on targeted therapies and CELMoD agents in multiple myeloma. Dr. Nisha Joseph offers an early ...

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...